Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUWOLFIA SERPENTINA vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension,Management of agitated psychotic states (historical use)
Hypertension
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Hepatic metabolism via CYP450 enzymes, with active metabolites (e.g., reserpine is metabolized by hydrolysis and conjugation); significant first-pass effect.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Plasma protein binding: approximately 80-90%, primarily to alpha1-acid glycoprotein and albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Vd: 0.5-1.0 L/kg. High tissue distribution, especially to adipose tissue and brain, correlating with extensive accumulation.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability: approximately 50% (range 30-60%) due to first-pass metabolism. Not administered parenterally in clinical practice.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Not studied; avoid use in severe renal impairment (GFR <30 m L/min) due to risk of accumulation and CNS effects.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in Child-Pugh A/B; consider 50% dose reduction.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended in children <12 years. For ages ≥12: 100 µg/kg twice daily, max 50 mg/dose.
Not established; avoid use in children.
Start at lowest dose (50 mg once daily) and titrate slowly; monitor for CNS depression, orthostatic hypotension, and depression.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
Risk of severe depression and suicide; use with caution in patients with history of depression. May cause bradycardia, electrolyte disturbances, and gastrointestinal bleeding. Avoid abrupt discontinuation to prevent withdrawal symptoms. Possible extrapyramidal symptoms and parkinsonism.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Active peptic ulcer, ulcerative colitis, history of depression (especially with suicidal tendencies), electroconvulsive therapy, pheochromocytoma, and concomitant MAO inhibitors.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as Rauwolfia may potentiate pressor effects. Limit alcohol intake. No specific food restrictions otherwise; but taking with food may reduce gastrointestinal upset.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Rauwolfia serpentina (reserpine) is Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimesters: May cause neonatal bradycardia, hypotonia, and nasal congestion due to placental transfer. Use only if benefit outweighs risk.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Rauwolfia alkaloids (reserpine) are excreted into breast milk. M/P ratio is not established. Avoid breastfeeding due to potential for infant hypotension, bradycardia, and extrapyramidal effects. Alternative therapy recommended.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No specific dose adjustments are established; however, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use lowest effective dose and monitor maternal response closely.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
1. Rauwolfia serpentina (reserpine) depletes catecholamines and serotonin from central and peripheral nerve endings; onset of action is slow (weeks) and offset prolonged. 2. Use cautiously in patients with history of peptic ulcer disease due to increased gastric acid secretion. 3. May cause significant bradycardia and orthostatic hypotension; monitor blood pressure and heart rate regularly. 4. Avoid concomitant use with MAOIs, tricyclic antidepressants, or sympathomimetics due to risk of hypertensive crisis. 5. Documented nasal congestion and sedation are common; consider alternative antihypertensives if tolerated poorly.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not stop suddenly as this may cause rapid rise in blood pressure.,Rise slowly from sitting or lying down to minimize dizziness from low blood pressure.,Avoid alcohol, which can worsen dizziness and drowsiness.,Report persistent nasal congestion, stomach pain, or unusual tiredness to your doctor.,Use caution when driving or operating machinery until you know how this medication affects you.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUWOLFIA SERPENTINA vs ALDORIL 25, answered by our medical review team.
RAUWOLFIA SERPENTINA is a Antihypertensive that works by Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUWOLFIA SERPENTINA and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUWOLFIA SERPENTINA is: Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUWOLFIA SERPENTINA and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUWOLFIA SERPENTINA is classified as Category C. Rauwolfia serpentina (reserpine) is Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third . ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.